Vera Therapeutics, Inc. (NASDAQ:VERA) Stock Has Average Target Price of $76.86

Vera Therapeutics, Inc. (NASDAQ:VERA) has earned a consensus rating of “Moderate Buy” from the fifteen analysts that are covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, two have issued a hold recommendation, eleven have assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price target among analysts that have issued a report on the stock in the last year is $74.93.

A number of research firms recently weighed in on VERA. Raymond James Financial set a $87.00 target price on shares of Vera Therapeutics in a report on Friday. Wall Street Zen raised shares of Vera Therapeutics from a “strong sell” rating to a “sell” rating in a report on Saturday. Cantor Fitzgerald restated an “overweight” rating on shares of Vera Therapeutics in a research report on Friday, October 23rd. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, September 15th. Finally, JPMorgan Chase & Co. upped their price target on shares of Vera Therapeutics from $76.00 to $83.00 and gave the stock an “overweight” rating in a report on Tuesday, September 8th.

Insider Transactions at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of the business’s stock in a transaction dated Tuesday, September 15th. The stock was sold at an average price of $37.00, for a total transaction of $684,500.00. Following the completion of the transaction, the chief executive officer directly owned 235,244 shares in the company, valued at $8,704,028. The trade was a 7.29% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 15.90% of the company’s stock.

Institutional Trading of Vera Therapeutics

Large investors have recently modified their holdings of the business. Allworth Financial LP increased its holdings in shares of Vera Therapeutics by 66.3% in the 3rd quarter. Allworth Financial LP now owns 1,515 shares of the company’s stock worth $49,000 after buying an additional 604 shares during the last quarter. Eurizon Capital SGR S.p.A. purchased a new stake in shares of Vera Therapeutics during the 3rd quarter valued at $32,000. Arizona State Retirement System raised its position in shares of Vera Therapeutics by 12.3% during the 2nd quarter. Arizona State Retirement System now owns 11,813 shares of the company’s stock valued at $507,000 after buying an additional 1,295 shares in the last quarter. ADAR1 Capital Management LLC lifted its holdings in shares of Vera Therapeutics by 8.8% during the 1st quarter. ADAR1 Capital Management LLC now owns 16,033 shares of the company’s stock worth $645,000 after acquiring an additional 1,300 shares during the last quarter. Finally, AMI Asset Management Corp lifted its holdings in shares of Vera Therapeutics by 4.7% during the 3rd quarter. AMI Asset Management Corp now owns 32,028 shares of the company’s stock worth $1,034,000 after acquiring an additional 1,446 shares during the last quarter. Institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Stock Down 0.0%

VERA stock opened at $29.78 on Monday. The company has a quick ratio of 10.92, a current ratio of 10.92 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $2.15 billion, a PE ratio of -5.05 and a beta of 1.07. Vera Therapeutics has a twelve month low of $23.86 and a twelve month high of $56.05. The stock has a 50-day simple moving average of $31.60 and a two-hundred day simple moving average of $36.68.

Vera Therapeutics (NASDAQ:VERA) last announced its quarterly earnings results on Thursday, November 5th. The company reported ($1.30) earnings per share for the quarter, beating the consensus estimate of ($1.62) by $0.32. The company had revenue of $10.28 million for the quarter, compared to the consensus estimate of $3.42 million. On average, equities analysts predict that Vera Therapeutics will post -6.45 EPS for the current fiscal year.

Key Stories Impacting Vera Therapeutics

Here are the key news stories impacting Vera Therapeutics this week:

• Positive Sentiment: For Q3 2026, Vera reported a loss of $1.30 per share, narrower than the $1.62 consensus loss, and revenue of $10.28 million versus estimates of $3.42 million. The earnings beats are supportive, although the company remained loss-making. Quarterly earnings report
• Positive Sentiment: HC Wainwright cut its price target to $75 from $90 but maintained a Buy rating. Its revised target still implies substantial upside from the cited $29.79 share price, which may offer support to investors. HC Wainwright rating update
• Neutral Sentiment: Vera granted stock options covering 14,900 shares and restricted stock units covering 7,450 shares to three new employees. The awards are a routine hiring incentive, with a small potential dilution effect. Inducement grants announcement
• Negative Sentiment: A valuation-focused article argues VERA may be above fair value after a 148% run, raising the risk that investors take profits or demand stronger progress to justify the share price. Valuation analysis
• Negative Sentiment: Although HC Wainwright remains bullish, its $15 reduction in the target reflects a more cautious view than before and may temper optimism. HC Wainwright rating update

Vera Therapeutics Company Profile

Vera Therapeutics, Inc is a clinical-stage biotechnology company focused on developing treatments for immunological diseases. The company’s research is centered on therapies that target the underlying causes of autoimmune conditions rather than primarily addressing their symptoms.

Vera’s lead product candidate is atacicept, a biologic designed to inhibit the B-cell survival factors BLyS and APRIL. The company has been evaluating atacicept in IgA nephropathy, an autoimmune kidney disease that can lead to progressive loss of kidney function, and has also investigated its potential in other immune-mediated diseases.